Rédaction Africa Links 24 with Damian Garde
Published on 2024-02-07 14:41:31
The need-to-know facts in biotech this morning include information on biotech earnings from Amgen and Gilead Sciences. BridgeBio Pharma granted Kyowa Kirin a license to co-develop an experimental drug for skeletal dysplasias in Japan. A biotech VC firm, Scion Life Sciences, raised $310 million for a new fund that will take a slow approach to investing.
According to STAT’s Adam Feuerstein, it is doubtful that Novartis’ latest deal with MorphoSys for the purchase of pelabresib will happen due to a doubtful path forward for the late-stage treatment for blood cancer.
Eli Lilly announced that its GLP-1-targeting medicine met its primary goal in a mid-stage study for obesity-related liver disease, but the reaction to this news has repercussions on other biotech companies working in the same field. Lilly’s stock price has doubled over the past 12 months, leading to the question of whether there is anywhere for the company to go but down from here.
Additionally, here are some more reads in the biotech world today:
– Aduhelm was a mess and it could happen again
– Novo Nordisk’s parent invests in India’s Manipal hospital chain
– Colombia proceeds with plans to issue a compulsory license for an HIV medicine sold by GSK’s ViiV
– Eisai falls behind on Leqembi patient goal
If you want to stay on top of the science and politics driving biotech today, sign up to get a biotech newsletter in your inbox. You can jump on our secret list and keep an eye out for the upcoming newsletter. Just some food for thought.
